| Literature DB >> 20175888 |
Frederic Raymond1, Sylviane Métairon, Martin Kussmann, Jaume Colomer, Andres Nascimento, Emma Mormeneo, Cèlia García-Martínez, Anna M Gómez-Foix.
Abstract
BACKGROUND: A high-sensitivity DNA microarray platform requiring nanograms of RNA input facilitates the application of transcriptome analysis to individual skeletal muscle (SM) tissue samples. Culturing myotubes from SM-biopsies enables investigating transcriptional defects and assaying therapeutic strategies. This study compares the transcriptome of aneurally cultured human SM cells versus that of tissue biopsies.Entities:
Mesh:
Year: 2010 PMID: 20175888 PMCID: PMC2838843 DOI: 10.1186/1471-2164-11-125
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Top regulated genes filtered by expression in skeletal muscle
| Gene ID | Gene Name | Description | FC |
|---|---|---|---|
| 4151 | MB | myoglobin | -2541 |
| 761 | CA3 | carbonic anhydrase III, muscle specific | -2391 |
| 29765 | TMOD4 | tropomodulin 4 (muscle) | -1564 |
| 4634 | MYL3 | myosin, light chain 3, alkali; ventricular, skeletal, slow | -1529 |
| 844 | CASQ1 | calsequestrin 1 (fast-twitch, skeletal muscle) | -1496 |
| 270 | AMPD1 | adenosine monophosphate deaminase 1 (isoform M) | -1320 |
| 4604 | MYBPC1 | myosin binding protein C, slow type | -1128 |
| 136371 | ASB10 | ankyrin repeat and SOCS box-containing 10 | -869.2 |
| 91977 | MYOZ3 | myozenin 3 | -841.6 |
| 4023 | LPL | lipoprotein lipase | -608.5 |
| 58529 | MYOZ1 | myozenin 1 | -546.7 |
| 53405 | CLIC5 | chloride intracellular channel 5 | -504.7 |
| 6271 | S100A1 | S100 calcium binding protein A1 | -366.4 |
| 57467 | HHATL | hedgehog acyltransferase-like | -364.5 |
| 57142 | RTN4 | reticulon 4 | -338.4 |
| 6123 | RPL3L | ribosomal protein L3-like | -317.8 |
| 200539 | ANKRD23 | ankyrin repeat domain 23 | -298.1 |
| 4892 | NRAP | nebulin-related anchoring protein | -294.9 |
| 123722 | FSD2 | fibronectin type III and SPRY domain containing 2 | -293.3 |
| 760 | CA2 | carbonic anhydrase II | -290.2 |
| 5837 | PYGM | phosphorylase, glycogen; muscle (McArdle syndrome, glycogen storage disease type V) | -277.4 |
| 84448 | ABLIM2 | actin binding LIM protein family, member 2 | -276.9 |
| 4618 | MYF6 | myogenic factor 6 (herculin) | -265.7 |
| 142689 | ASB12 | ankyrin repeat and SOCS box-containing 12 | -228.6 |
| 339456 | TMEM52 | transmembrane protein 52 | -217.2 |
| 129446 | XIRP2 | xin actin-binding repeat containing 2 | -216.1 |
| 26287 | ANKRD2 | ankyrin repeat domain 2 (stretch responsive muscle) | -200.5 |
| 712 | C1QA | complement component 1, q subcomponent, A chain | -197.9 |
| 10840 | ALDH1L1 | aldehyde dehydrogenase 1 family, member L1 | -196.1 |
| 9452 | ITM2A | integral membrane protein 2A | -178.5 |
| 5104 | SERPINA5 | serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 | -175.8 |
| 825 | CAPN3 | calpain 3, (p94) | -164.2 |
| 4653 | MYOC | myocilin, trabecular meshwork inducible glucocorticoid response | -162.9 |
| 55335 | NIPSNAP3B | nipsnap homolog 3B (C. elegans) | -161.9 |
| 361 | AQP4 | aquaporin 4 | -160.4 |
| 4129 | MAOB | monoamine oxidase B | -158.9 |
| 1375 | CPT1B | carnitine palmitoyltransferase 1B (muscle) | -151.4 |
| 3743 | KCNA7 | potassium voltage-gated channel, shaker-related subfamily, member 7 | -137.9 |
| 57214 | KIAA1199 | KIAA1199 | +1279 |
| 5806 | PTX3 | pentraxin-related gene, rapidly induced by IL-1 beta | +491.7 |
| 1026 | CDKN1A | cyclin-dependent kinase inhibitor 1A (p21, Cip1) | +192.8 |
| 114801 | TMEM200A | transmembrane protein 200A | +184.9 |
| 2335 | FN1 | fibronectin 1 | +82.93/43.39D |
| 23362 | PSD3 | pleckstrin and Sec7 domain containing 3 | +82.63 |
| 124565 | SLC38A10 | solute carrier family 38, member 10 | +68.68 |
| 7077 | TIMP2 | TIMP metallopeptidase inhibitor 2 | +68.09 |
| 7153 | TOP2A | topoisomerase (DNA) II alpha 170kDa | +43.58 |
| 8985 | PLOD3 | procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 | +43.02 |
| 6505 | SLC1A1 | solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1 | +40.97 |
| 9663 | LPIN2 | lipin 2 | +40.92 |
| 54480 | CSGlcAT | chondroitin sulfate glucuronyltransferase | +39.96 |
| 338773 | TMEM119 | transmembrane protein 119 | +38.12 |
| 5352 | PLOD2 | procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 | +36.07/25.77D |
| 493869 | GPX8 | glutathione peroxidase 8 | +35.9 |
| 3091 | HIF1A | hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | +34.89 |
| 115908 | CTHRC1 | collagen triple helix repeat containing 1 | +33.74 |
| 8572 | PDLIM4 | PDZ and LIM domain 4 | +31.9 |
| 151887 | CCDC80 | coiled-coil domain containing 80 | +31.02/17.06D |
| 4323 | MMP14 | matrix metallopeptidase 14 (membrane-inserted) | +29.75 |
| 23114 | NFASC | neurofascin homolog (chicken) | +26.53 |
| 55165 | CEP55 | centrosomal protein 55kDa | +25.73 |
| 5270 | SERPINE2 | serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 | +24.59 |
| 54431 | DNAJC10 | DnaJ (Hsp40) homolog, subfamily C, member 10 | +24.52 |
| 6695 | SPOCK1 | sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1 | +24.35 |
| 2629 | GBA | glucosidase, beta; acid (includes glucosylceramidase) | +24.33 |
| 7421 | VDR | vitamin D (1,25- dihydroxyvitamin D3) receptor | +23.83 |
| 4643 | MYO1E | myosin IE | +23.46 |
| 166929 | SGMS2 | sphingomyelin synthase 2 | +22.63 |
| 7058 | THBS2 | thrombospondin 2 | +22.59 |
The list includes the 10% most differentially expressed genes in cultured myotubes compared to SM tissue. The set of the 1260 regulated gene transcripts, including replicated genes, was selected on the basis of their expression in SM, according to the IPA knowledge-base and the fold-change and was ordered by the magnitude of the fold change. For each gene, the fold change in gene expression was calculated between mean values in cultured myotubes versus SM biopsy. Duplicated genes on the microarray are marked (D) and the two values are shown. The significance of differences was estimated by a Benjamini-Hochberg corrected paired t-test (p < 0.01). The first column lists the ID for Entrez Gene, the second the gene name, the third the description of the gene and the fourth the fold change (FC) with a negative symbol for downregulated genes and a positive symbol for upregulated genes.
Genes validated for differential expression
| Gene ID | Gene Name | Description | FCM | FCV |
|---|---|---|---|---|
| 29765 | TMOD4 | tropomodulin 4 (muscle) | -1564 | -3065* |
| 270 | AMPD1 | adenosine monophosphate deaminase 1 (isoform M) | -1320 | -2799* |
| 4604 | MYBPC1 | myosin binding protein C, slow type | -1128 | -1574* |
| 58529 | MYOZ1 | myozenin 1 | -546.7 | -3449* |
| 5837 | PYGM | phosphorylase, glycogen; muscle | -277.4 | -3444** |
| 4618 | MYF6 | myogenic factor 6 (herculin) | -265.7 | -258.8* |
| 129446 | XIRP2 | xin actin-binding repeat containing 2 | -216.1 | -498.5* |
| 825 | CAPN3 | calpain 3, (p94) | -164.2 | -497.9* |
| 1375 | CPT1B | carnitine palmitoyltransferase 1B (muscle) | -151.4 | -109.5* |
| 7352 | UCP3 | uncoupling protein 3 (mitochondrial, proton carrier) | -106.5 | -2086** |
| 55303 | GIMAP4 | GTPase, IMAP family member 4 | -71.28 | -146.3* |
| 7070 | THY1 | Thy-1 cell surface antigen | +16.67 | +18.15* |
| 151887 | CCDC80 | coiled-coil domain containing 80 | +31.02/17.06D | +7.04* |
| 3091 | HIF1A | hypoxia-inducible factor 1, alpha subunit | +34.89 | +19.62* |
| 7153 | TOP2A | topoisomerase (DNA) II alpha 170kDa | +43.58 | +5.83* |
| 1026 | CDKN1A | cyclin-dependent kinase inhibitor 1A (p21, Cip1) | +192.8 | +31.67* |
| 57214 | KIAA1199 | KIAA1199 | +1279 | +370.6* |
List of genes with changed expression as validated by RT and real-time PCR (PYGM, UCP3, THY1) or QuantiGene Plex (the remaining genes). For each targeted gene, the expression was determined relative to the B2M (in RT and real-time PCR) or TFRC (in QuantiGene Plex) genes. Similar data were obtained with QuantiGene Plex when the B2M gene was used as a control (data not shown). For each gene, the fold change in gene expression was calculated between mean values in cultured myotubes versus SM biopsy. The significance of differences was estimated by a paired t-test: *p < 0.01 and **p < 0.005. The first, second and third columns are as in Table 1, the fourth lists the fold change in the microarray (FCM) as in Table 1 and the fifth the fold change in the validation techniques (FCV), with a negative symbol for downregulated genes and a positive symbol for upregulated genes. The Pearson correlation coefficient between FCM and FCV values is 0.684 (including the two copies of the CCDC80 gene).
Figure 1Chromosome distribution and clusters of enriched regulated genes. We used the GeneSpring GX program to obtain the chromosome and genomic position of the 1216 differentially expressed genes. Of these, 983 had chromosome annotations. Data were analyzed with the REEF program, with a window width of 1 M, a shift of 200 k, a Q-value of 0.05 and a minimum number of transcripts in clusters of 2. We used the REEF Reference file as reference features. (A) The number of regulated genes is plotted against each annotated chromosome. (B) The image shows the list of chromosomes in the analyzed samples and a representation of the position of clusters of enriched features as red squares. The last line that corresponds to the Y chromosome is not listed. (C) Selected genes in the cluster on chromosome 7 position 149600000 - 151000000 (p-value ≤ 2.117e-004). The first column lists the ID for Entrez Gene, the second column the gene name, the third column the gene description, the fourth column the fold change (FC) with a negative symbol for downregulated genes and a positive symbol for upregulated genes, and the fifth column indicates whether these genes are expressed in SM according to IPA (positive symbol). The cluster on chromosome 1, position 114200000 - 115800000 (p-value ≤ 1.612e-004) was composed of OLFML3, DENND2C, AMPD1, NRAS and CSDE1. The cluster on chromosome 20, position 29400000 - 30600000 (p-value ≤ 9.859e-005) included HM13, COX4I2, MYLK2, C20orf160 and POFUT1.
Significantly regulated canonical pathways
| Score | Ratio | Number of Focus Genes | |
|---|---|---|---|
| Mitochondrial Dysfunction | 7.88 | 17.60% | 30 |
| Integrin Signaling | 3.52 | 14.50% | 28 |
| Hepatic Fibrosis/Hepatic Stellate Cell Activation | 2.38 | 14.10% | 19 |
| Caveolar-mediated Endocytosis | 2.02 | 14.80% | 12 |
| Regulation of Actin-based Motility by Rho | 1.77 | 13.00% | 12 |
| Actin Cytoskeleton Signaling | 1.46 | 10.40% | 23 |
| Apoptosis Signaling | 1.35 | 12.10% | 11 |
| Circadian Rhythm Signaling | 1.31 | 15.60% | 5 |
| p53 Signaling | 1.29 | 12.60% | 11 |
| PTEN Signaling | 1.29 | 11.70% | 11 |
| Citrate Cycle | 6.27 | 20.30% | 12 |
| Oxidative Phosphorylation | 4.61 | 15.90% | 25 |
| Ubiquinone Biosynthesis | 3.66 | 12.50% | 13 |
| Glycolysis/Gluconeogenesis | 3.39 | 12.10% | 17 |
| Pyruvate Metabolism | 3.15 | 9.66% | 14 |
| Tyrosine Metabolism | 3.01 | 6.45% | 12 |
| Butanoate Metabolism | 2.61 | 8.53% | 11 |
| One Carbon Pool by Folate | 2.51 | 15.80% | 6 |
| Glycosaminoglycan Degradation | 1.85 | 9.84% | 6 |
| Biosynthesis of Steroids | 1.78 | 4.72% | 6 |
| Alanine and Aspartate Metabolism | 1.67 | 9.30% | 8 |
| Propanoate Metabolism | 1.54 | 7.14% | 9 |
| Lysine Degradation | 1.34 | 6.25% | 9 |
Canonical pathways that have significant associations with the whole set of regulated transcripts were assessed using IPA software. The scores are shown as -log(p-value) in order to show positive numbers. The p-value was calculated by IPA using Fisher's Exact Test. A threshold value of 1.3 was selected (p-value < 0.05). The first column lists the signaling or metabolic pathways; the second the score value; the third the ratio, which represents the proportion of genes from the dataset over the total number of genes in the pathway; and the fourth the number of focus genes.
Figure 2Mitochondrial dysfunction. Graphical representation of the differentially expressed genes in cultured myotubes compared to SM tissue and their molecular relationships. Genes are represented as nodes. Node color indicates the direction of change of gene expression. Downregulated genes are highlighted in green and upregulated genes in red. Color intensity corresponds to the magnitude of change. Nodes are displayed using various shapes that represent the functional class of the gene product. The lines in between genes represent known interactions. The pathway image was created using IPA software.
Figure 3PTEN signaling pathway. Graphical representation of the differentially expressed genes in cultured myotubes compared to SM tissue and their molecular relationships. Genes are represented as nodes. Node color indicates the direction of change of gene expression. Downregulated genes are highlighted in green and upregulated genes in red. Color intensity corresponds to the magnitude of change. Nodes are displayed using various shapes that represent the functional class of the gene product. The lines in between genes represent known interactions. The pathway image was created using IPA software.